CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ionis Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ionis Pharmaceuticals Inc
2855 Gazelle Court
Phone: (760) 931-9200p:760 931-9200 CARLSBAD, CA  92010  United States Ticker: IONSIONS

Business Summary
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board JosephLoscalzo 71 6/3/2021 2/3/2014
Chief Executive Officer, Director Brett P.Monia 61 1/1/2020 2/1/2009
Chief Financial Officer, Executive Vice President - Finance Elizabeth L.Hougen 61 1/1/2021 1/1/2013
12 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Akcea Therapeutics Inc 22 Boston Wharf Rd Bostonn MA United States

Business Names
Business Name
Akcea Therapeutics Canada Inc.
Akcea Therapeutics Germany GmbH
Akcea Therapeutics Ireland Limited
13 additional Business Names available in full report.

General Information
Number of Employees: 927 (As of 2/15/2024)
Outstanding Shares: 145,751,797 (As of 2/15/2024)
Shareholders: 476
Stock Exchange: NASD
Federal Tax Id: 330336973
Fax Number: (302) 655-5049
Email Address: info@isisph.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024